Baricitinib Completed Phase 2 Trials for Skin Diseases, Papulosquamous / Skin Diseases / Psoriasis Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01490632A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis